{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants experienced events","groupId":"OG000","lowerLimit":"15.61","upperLimit":"NA","value":"55.66"},{"comment":"Insufficient number of participants experienced events","groupId":"OG001","lowerLimit":"4.57","upperLimit":"NA","value":"32.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.","dispersionType":"Inter-Quartile Range","groups":[{"description":"brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone brentuximab vedotin: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles","id":"OG000","title":"A+CHP"},{"description":"cyclophosphamide, doxorubicin, vincristine, and prednisone doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles vincristine: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles","id":"OG001","title":"CHOP"}],"paramType":"MEDIAN","populationDescription":"This analysis population includes only patients with systemic anaplastic large cell lymphoma (sALCL).","reportingStatus":"POSTED","timeFrame":"Up to 60 months","title":"Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)","type":"SECONDARY","unitOfMeasure":"months"}